At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 78 enrolled
Drug / intervention
VIB4920 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA)
In Brief
A Phase 2 clinical trial evaluating VIB4920 and Placebo for Rheumatoid Arthritis. Completed, enrolled 78 participants across 25 sites in 2 countries.
Detailed Summary
The purpose of the study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of VIB4920 (formerly MEDI4920) in adult participants with rheumatoid arthritis (RA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesPoland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartDec 2019
Primary CompletionDec 2021
TodayJul 2026
First PostedNov 15, 2019
Enrollment StartDec 9, 2019
Primary CompletionDec 28, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.6 years ago
Interventions
VIB4920drug
liquid for IV infusion following dilution in normal saline
Placebodrug
0.9% saline for IV infusion